Pharma Industry

Pricing and Market Access Considerations for Cell and Gene

2020-03-04T22:43:35+00:00February 27th, 2020|Categories: Blog|Tags: , , , |

Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]

An Overview of Cell and Gene Therapies

2020-03-04T13:53:10+00:00February 24th, 2020|Categories: Blog|Tags: , , , |

An Overview of Cell and Gene Therapies Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration. Gene Therapy Launch Timeline Gene Therapy Product Overview Product Indication Therapy Type Price Kymriah Childhood B-cell acute lymphoblastic leukemia (ALL) Diffuse large B-cell lymphoma (DLBCL) CAR-T [...]

Two Labs Acquires CEEK Enterprises

2020-03-04T13:53:57+00:00February 6th, 2020|Categories: Blog|Tags: , |

At Two Labs, our mission is to improve patients’ quality of life by delivering innovative trade and commercialization services to pharmaceutical manufacturers. This is why we’re pleased to announce that as of February 3, 2020, Two Labs has acquired CEEK Enterprises, a management consultancy focused on biopharma/med tech with specialized expertise in corporate development, commercial strategy, clinical development and medical affairs. This acquisition strengthens our mission by adding complementary [...]

Two Labs Acquires CEEK Enterprises

2020-03-04T13:54:20+00:00February 6th, 2020|Categories: News|Tags: , |

Originally posted on PR Newswire Two Labs Acquires CEEK Enterprises Company enhances services for biopharma clients with CEEK's complementary suite of management consulting expertise COLUMBUS, Ohio, Feb. 6, 2020 /PRNewswire/ -- Two Labs, an industry-leading pharma services company, today announced that it has acquired CEEK Enterprises, a management consultancy dedicated to supporting clients in the biopharma and MedTech industries with specialized expertise in corporate development, commercial strategy, clinical development [...]

What manufacturers need to know about Minnesota House Bill 400

2020-02-25T18:21:55+00:00July 30th, 2019|Categories: Blog|Tags: , |

We recently notified our clients and partners of several regulatory changes that will affect manufacturers and wholesalers doing business in Minnesota. In May 2019, Minnesota Governor Tim Walz signed House Bill 400, which created an Opioid Stewardship Advisory Council to confront the opioid addiction crisis and overdose epidemic. Parts of the law are already in effect as of July 1, 2019, and more pieces of the bill will [...]

New regulation requirements impacting your license

2020-02-25T18:22:58+00:00June 4th, 2019|Categories: Blog|Tags: , |

In the pharmaceutical industry, state licensing requirements can change at a moment’s notice. Though no central “hub” exists listing all licensing updates for each state, our team of experts works with state boards on a routine basis to track all license requirement updates. Recently, we’ve notified our clients and partners of changes that affect virtual manufacturers specifically in Arizona, Vermont, and New Hampshire. Government agencies in these states [...]

Current and Future Oncology Management in the United States

2020-03-02T20:05:08+00:00February 7th, 2019|Categories: News|Tags: |

Originally posted by the Journal of Managed Care & Specialty Pharmacy Volume 25 Issue (2) Anne Runyan, BA; Jordan Banks, MPA; and Daniele Severi Bruni, MS MKO Global Partners, Powell, Ohio. J Manag Care Spec Pharm, 2019 Feb;25(2):272-281. Abstract BACKGROUND: The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital [...]

Current and Future Oncology Management in the United States

2020-02-26T13:56:46+00:00February 1st, 2019|Categories: Blog|Tags: , |

The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. This study focuses on the cost of medication from the viewpoint of U.S. payers. Although new tools for managing these costs have been gaining attention, prices continue to rise, and [...]

Innovative Access Agreements

2020-05-13T15:05:43+00:00January 1st, 2019|Categories: Blog|Tags: , , |

A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The [...]

NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

2020-03-02T20:05:42+00:00November 1st, 2018|Categories: News|Tags: |

With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021. With more than 46,000 patients in the UK and an annual cost of greater than £400 million, Humira represents the largest spend on a single drug by the NHS and a significant opportunity [...]

Comments Off on NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab